A Food and Drug Administration official last week harshly criticized a major clinical trial for the popular diabetes drug Avandia, saying that the drug maker ignored numerous cases of patients suffering heart problems during the trial. The examiner said he found a dozen instances that point to Avandia causing heart attacks and strokes in patients, which seconds the criticism of many of the drug’s critics. A panel will meet next week to decide if a recommendation should be made to the FDA that Avandia be withdrawn from the market.